期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 18, 期 6, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2114254
关键词
CAR; CAR T-cell therapy; structure; generations; approval; clinical trials
CAR T-cell therapy is a customized immunotherapy that equips T-cells with CARs to target cancer cells, offering potential curative effects. However, there are several hurdles limiting its broader implications.
Chimeric antigen receptor (CAR) T-cell therapy is a novel, customized immunotherapy that is considered a 'living' and self-replicating drug to treat cancer, sometimes resulting in a complete cure. CAR T-cells are manufactured through genetic engineering of T-cells by equipping them with CARs to detect and target antigen-expressing cancer cells. CAR is designed to have an ectodomain extracellularly, a transmembrane domain spanning the cell membrane, and an endodomain intracellularly. Since its first discovery, the CAR structure has evolved greatly, from the first generation to the fifth generation, to offer new therapeutic alternatives for cancer patients. This treatment has achieved long-term and curative therapeutic efficacy in multiple blood malignancies that nowadays profoundly change the treatment landscape of lymphoma, leukemia, and multiple myeloma. But CART-cell therapy is associated with several hurdles, such as limited therapeutic efficacy, little effect on solid tumors, adverse effects, expensive cost, and feasibility issues, hindering its broader implications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据